Crossmark

PFKP is required for chemoresistant phenotype of breast cancer through modulating the formation of CD133+ cancer stem like cells

Published Online: 2026-04-23

Authors

Fang, Kai

Ma, Yue

Li, Lihua

Yue, Yan

Ruan, Hang https://orcid.org/0000-0001-7506-3805
Xiong, Sidong
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (32100523)

the Priority Academic Program Development of Jiangsu Higher Education Institutions

Wuxi Taihu Lake Talent Plan, Supports for Leading Talents in Medical and Health Profession

Interdisciplinary Basic Frontier Innovation Program of Suzhou Medical College of Soochow University (YXY2303026)
License Information

Text and Data Mining valid from 2026-04-23

Version of Record valid from 2026-04-23
More Information

Article History

Received: 31 July 2025

Revised: 15 April 2026

Accepted: 15 April 2026

First Online: 23 April 2026

Declarations

:

: Written informed consent was obtained from all participants. This study was conducted with the approval of the Institutional Review Board and in compliance with the Declaration of Helsinki. The Ethics Committee of the Affiliated Hospital of Jiangnan University granted approval (License number: LS2020064) for human tissues, and granted approval (License number: 20220009025212) for animal experiments.

: NA.

: The authors declare that they have no competing interests.

Document is current